PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

Abstract Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.
PMID
Related Publications

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.

Statin induced myopathy.

A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Management of the patient with statin intolerance.

Authors

Mayor MeshTerms
Keywords

cardiovascular disease

low-density lipoprotein

myalgia

myopathy

statin intolerance

Journal Title journal of the american college of cardiology
Publication Year Start




PMID- 28859793
OWN - NLM
STAT- MEDLINE
DA  - 20170901
DCOM- 20170913
LR  - 20170913
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 70
IP  - 10
DP  - 2017 Sep 05
TI  - Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
PG  - 1290-1301
LID - S0735-1097(17)38966-0 [pii]
LID - 10.1016/j.jacc.2017.07.752 [doi]
AB  - Statins are highly effective for preventing cardiovascular events by reducing
      low-density lipoprotein cholesterol (LDL-C). However, many patients taking
      statins report muscle-related symptoms that prevent the use of guideline
      recommended doses. Patients with reported intolerance to statins have a high risk
      of cardiovascular events. Clinical strategies that optimize cardiovascular risk
      reduction through LDL-C lowering need to be applied in patients experiencing
      intolerable side effects that they attribute to statins. In this paper, the
      authors review definitions of statin intolerance, propose algorithms to better
      define statin intolerance, and describe approaches to optimize cardiovascular
      risk reduction among individuals reporting statin-associated muscle symptoms.
CI  - Copyright (c) 2017 American College of Cardiology Foundation. All rights
      reserved.
FAU - Rosenson, Robert S
AU  - Rosenson RS
AD  - Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount
      Sinai, New York, New York. Electronic address: [email protected]
FAU - Baker, Steven
AU  - Baker S
AD  - Department of Medicine, Neuromuscular Disease Clinic, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Banach, Maciej
AU  - Banach M
AD  - Department of Hypertension, Medical University of Lodz, Lodz, Poland;
      Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
FAU - Borow, Kenneth M
AU  - Borow KM
AD  - National Medication Safety, Outcomes and Adherence Program, MediMergent,
      Rockville, Maryland.
FAU - Braun, Lynne T
AU  - Braun LT
AD  - Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush
      University Medical Center, Chicago, Illinois.
FAU - Bruckert, Eric
AU  - Bruckert E
AD  - Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department,
      Hopital Pitie Salpetriere, Paris, France.
FAU - Brunham, Liam R
AU  - Brunham LR
AD  - Department of Medicine, University of Vancouver, British Columbia, Canada.
FAU - Catapano, Alberico L
AU  - Catapano AL
AD  - Department of Pharmacological and Biomolecular Sciences, University of Milan,
      IRCCS Multimedica, Milan, Italy.
FAU - Elam, Marshall B
AU  - Elam MB
AD  - Departments of Pharmacology and Medicine, University of Tennessee Health Sciences
      Center, Memphis, Tennessee.
FAU - Mancini, G B John
AU  - Mancini GBJ
AD  - Department of Medicine, Division of Cardiology, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Moriarty, Patrick M
AU  - Moriarty PM
AD  - Division of Clinical Pharmacology, Division of Internal Medicine, University of
      Kansas Medical Center, Kansas City, Kansas.
FAU - Morris, Pamela B
AU  - Morris PB
AD  - Department of Medicine, Division of Cardiology, Medical University of South
      Carolina, Charleston, South Carolina.
FAU - Muntner, Paul
AU  - Muntner P
AD  - Department of Epidemiology, University of Alabama Birmingham, Birmingham,
      Alabama.
FAU - Ray, Kausik K
AU  - Ray KK
AD  - Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care
      and Public Health, Imperial College London, London, United Kingdom.
FAU - Stroes, Erik S
AU  - Stroes ES
AD  - Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.
FAU - Taylor, Beth A
AU  - Taylor BA
AD  - Department of Kinesiology, University of Connecticut, Storrs, Connecticut;
      Division of Cardiology, Hartford Hospital, Hartford, Connecticut.
FAU - Taylor, Valerie H
AU  - Taylor VH
AD  - Department of Psychiatry, University of Toronto, Women's College Hospital,
      Toronto, Ontario, Canada.
FAU - Watts, Gerald F
AU  - Watts GF
AD  - Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School
      of Medicine, University of Western Australia, Perth, Western Australia.
FAU - Thompson, Paul D
AU  - Thompson PD
AD  - Division of Cardiology, Hartford Hospital, Hartford, Connecticut.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - AIM
SB  - IM
MH  - Anticholesteremic Agents/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Cholesterol/*blood
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use
MH  - Muscle, Skeletal/*drug effects
MH  - Muscular Diseases/*chemically induced
MH  - Risk Factors
OTO - NOTNLM
OT  - cardiovascular disease
OT  - low-density lipoprotein
OT  - myalgia
OT  - myopathy
OT  - statin intolerance
EDAT- 2017/09/02 06:00
MHDA- 2017/09/14 06:00
CRDT- 2017/09/02 06:00
PHST- 2017/05/21 [received]
PHST- 2017/07/20 [revised]
PHST- 2017/07/21 [accepted]
AID - S0735-1097(17)38966-0 [pii]
AID - 10.1016/j.jacc.2017.07.752 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. doi: 10.1016/j.jacc.2017.07.752.